is a tumour
of the pancreas
derived from the beta cells
which while retaining the ability to synthesize and secrete insulin
is autonomous of the normal feedback mechanisms. Patients present with symptomatic hypoglycemia
which is ameliorated by feeding. The diagnosis of an insulinoma is usually made biochemically with low blood sugar, elevated insulin, pro-insulin and C-peptide levels and confirmed by medical imaging
or angiography. The definitive treatment is surgery.
Insulinomas are rare neuroendocrine tumours
with an incidence estimated at 1 to 4 new cases per million persons per year. Insulinoma is one of the most common types of tumour arising from the islets of Langerhans
cells (pancreatic endocrine tumours). Estimates of malignancy (metastases) range from 5% to 30%. Over 99% of insulinomas originate in the pancreas, with rare cases from ectopic pancreatic tissue. About 5% of cases are associated with tumours of the parathyroid glands and the pituitary (Multiple endocrine neoplasia type 1
) and are more likely to be multiple and malignant. Most insulinomas are small, less than 2 cm.
Signs and Symptoms
Patients with insulinomas usually develop neuroglycopenic symptoms. These include recurrent headache, lethargy, diplopia
, and blurred vision, particularly with exercise or fasting. Severe hypoglycemia may result in seizures
, and permanent neurological damage. Symptoms resulting from the catecholaminergic response to hypoglycemia (i.e. tremulousness, palpitations, tachycardia
, sweating, hunger, anxiety, nausea) are not as common. Sudden weight gain (the patient can become massively obese) is sometimes seen.
The diagnosis of insulinoma is suspected in a patient with symptomatic fasting hypoglycemia. The conditions of Whipple’s triad
need to be met for the diagnosis of "true hypoglycemia" to be made:
- symptoms and signs of hypoglycemia,
- concomitant plasma glucose level of 45 mg/dL (2.5 mmol/L) or less, and
- reversibility of symptoms with administration of glucose.
The following blood tests are needed to diagnose insulinoma:
If available, a proinsulin level might be useful as well. Other blood tests may help rule out other conditions which can cause hypoglycemia.
Normally, endogenous insulin production is suppressed in the setting of hypoglycemia. A 72-hour fast, usually supervised in a hospital setting, can be done to see if insulin levels fail to suppress, which is a strong indicator of the presence of an insulin-secreting tumour.
- During the test, the patient may have calorie-free and caffeine-free liquids. Capillary blood glucose is measured every 4 hours using a reflectance meter, until values < 60 mg/dL (3.3 mmol/L) are obtained. Then, the frequency of blood glucose measurement is increased to every hour until values are < 49 mg/dL (2.7 mmol/L). At that point, or when the patient has symptoms of hypoglycemia, a blood test is drawn for serum glucose, insulin, proinsulin, and C-peptide levels. The fast is stopped at that point, and the hypoglycemia treated with intravenous dextrose or calorie-containing food or drink.
The insulinoma might be localized by non-invasive means, using ultrasound
, CT scan
, or by MRI
techniques. An Indium-111 pentetreotide scan is more sensitive than ultrasond, CT, or MRI for detection of somatostatin receptor positive tumors.
Sometimes, angiography with percutaneous transhepatic pancreatic vein catheterization to sample the blood for insulin levels is required. Calcium can be injected into selected arteries to stimulate insulin release from various parts of the pancreas, which can be measured by sampling blood from their respective veins. The use of calcium stimulation improves the specificity of this test.
During surgery to remove an insulinoma, an intra-operative ultrasound can sometimes localize the tumour, which helps guide the surgeon in the operation and has a higher sensitivity than noninvasive imaging tests.
The definitive management is surgical removal of the insulinoma. This may involve removing part of the pancreas as well (Whipple procedure
and distal pancreatectomy
Medications such as diazoxide
can be used to block the release of insulin for patients who are not surgical candidates or who otherwise have inoperable tumours.
is used in islet cell carcinomas
which produce excessive insulin. Combination chemotherapy
is used: either doxorubicin
+ streptozotocin, or fluorouracil
+ streptotozocin in patients where doxorubicin is contraindicated.
In metastasizing tumours with intrahepatic growth, hepatic arterial
occlusion or embolization
can be used.
Most patients with benign insulinomas can be cured with surgery. Persistent or recurrent hypoglycemia after surgery tends to occur in patients with multiple tumours. About two percent of patients develop diabetes mellitus
after their surgery.
Hypoglycemia was first recognized in the 19th century. In the 1920’s, after the discovery of insulin and its use in the treatment of diabetics, hyperinsulinism was suspected to be a cause of hypoglycemia in non-diabetics. The first report of a surgical cure of hypoglycemia by removing an islet cell tumour was in 1929.